Halo Pharmaceutical Completes $14.6 Million in Financing from The Prov...(lifecycle extension is possible through ...),Health

Date:4/22/2009

lifecycle extension is possible through sustained release formulation development; the addition of appropriate dosage forms and strengths; the development of new indications; and new approaches to promotion of the brands. Halo also offers full service state-of-the-art contract manufacturing in a wide range of dosage forms, formulation and analytical method development from pre-clinical through phase III, and laboratory testing services to the pharmaceutical and related industries. Halo is currently a supplier of choice to a number of large and medium size brand pharmaceutical companies for important lifecycle products. Contract manufacturing capabilities include the ability to conduct aseptic semi solids manufacturing and filling, granulation, blending, tableting, coating and packaging. DEA Schedule 2 to 5 products can also be manufactured and packaged. Halo also has related warehousing and distribution operations. Halo Pharmaceutical is a privately-held company.

About The Provident Bank

With $4.2 billion in deposits, The Provident Bank serves its customers via a network of 82 branches throughout northern and central New Jersey. The Provident Bank is the wholly owned subsidiary of Provident Financial Services, Inc. (NYSE: PFS), which reported assets of $6.6 billion as of December 31, 2008.

'/>"/>

SOURCE Halo Pharmaceutical Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine news :

1. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
2. Genesis Pharmaceuticals Announces the Launch of Three TCM Products
3. Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
4. WellSpring Pharmaceutical Corp. Emetrol(R) Consumer Brand Achieves Number One Position in Anti-Nausea Category
5. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
6. Tianyin Pharmaceutical Co. Inc.s Ginkgo Mihuan Oral Solution Completes 2009 Tenders
7. Par Pharmaceutical Enters Into Agreement With Reliant Pharmaceuticals to Settle Patent Litigation Over Rythmol(R) SR
8. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
9. Strativa Pharmaceuticals Provides Product Pipeline Update
10. Halo Pharmaceutical Welcomes Dr. George Bobotas as Its Chief Scientific Officer
11. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2009 Financial Results